Concentrations of scheduled prescription drugs in blood of impaired drivers: Considerations for interpreting the results

Therapeutic Drug Monitoring

Volumn 29, Issue 2, 2007, Pages 248-260

  Jones, A W ^a,b   Holmgren, A ^a   Kugelberg, F C ^a  

^a National Board of Forensic Medicine   (Sweden)

^b Department of Forensic Genetics and Forensic Toxicology   (Sweden)

Author keywords

Driving; DUID; Prescription medication; Scheduled drugs; Therapeutic drug monitoring

Indexed keywords

ALIMEMAZINE; ALPRAZOLAM; BENZODIAZEPINE DERIVATIVE; BUPRENORPHINE; CARBAMAZEPINE; CARISOPRODOL; CHLORDIAZEPOXIDE; CLONAZEPAM; CODEINE; DEXTROPROPOXYPHENE; DIAZEPAM; EPHEDRINE; ETHYLMORPHINE; FLUNITRAZEPAM; HYDROXYZINE; HYPNOTIC AGENT; MEPROBAMATE; METHADONE; MIDAZOLAM; MORPHINE; NITRAZEPAM; NORDAZEPAM; OXAZEPAM; PHENOBARBITAL; PHENYTOIN; PSYCHOTROPIC AGENT; TRAMADOL; UNINDEXED DRUG; ZOLPIDEM; ZOPICLONE;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CAR DRIVING; DEMOGRAPHY; DRIVER; DRUG BLOOD LEVEL; DRUG STABILITY; ENZYME POLYMORPHISM; FORENSIC MEDICINE; HEMATOCRIT; HUMAN; KIDNEY FUNCTION; LIVER FUNCTION; PRESCRIPTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SWEDEN; TOXICOLOGY;

AUTOMOBILE DRIVING; DRUG MONITORING; DRUGS, NON-PRESCRIPTION; HUMANS; OVERDOSE; PHARMACEUTICAL PREPARATIONS; PRESCRIPTIONS, DRUG; PSYCHOTROPIC DRUGS; STREET DRUGS; SUBSTANCE ABUSE DETECTION; SWEDEN;

EID: 34248191277     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/FTD.0b013e31803d3c04     Document Type: Article

References (90)

1. Jones AW. Driving under the influence of drugs in Sweden with zero-concentration limits in blood for controlled substances. Traffic Inj Prev. 2005;6:317-322.
2. Walsh JM, de Gier JJ, Christopherson AS, et al. Drugs and driving. Traffic Inj Prev. 2004;5:241-253.
3. Moeller MR, Kraemer T. Drugs of abuse monitoring in blood for control of driving under the influence of drugs. Ther Drug Monit. 2002;24:210-221.
4. Augsburger M, Donze N, Menetrey A, et al. Concentrations of drugs in blood of suspected impaired drivers. Forensic Sci Int. 2005;153:11-15.
5. Repetto MR, Repetto M. Therapeutic, toxic, and lethal concentrations of 73 drug affecting respiratory system in human fluids. J Toxicol Clin Toxicol. 1998;36:287-293.
6. Repetto MR, Repetto M. Concentrations in human fluids: 101 drugs affecting the digestive system and metabolism. J Toxicol Clin Toxicol. 1999;37:1-8.
7. Winek CL, Wahba WW, Winek CL Jr. Drug and chemical blood level data. Forensic Sci Int. 2001;122:107-123.
8. Stead AH, Moffat AC. A collection of therapeutic, toxic and fatal blood drug concentrations in man. Hum Toxicol. 1983;2:437-464.
9. Uges DRA. Therapeutic and toxic drug concentrations. Bull Int Assoc Forensic Toxicol. 1996;26(Suppl):1-34.
10. Druid H, Holmgren P. A compilation of fatal and control concentrations of drugs in postmortem femoral blood. J Forensic Sci. 1997;42:79-87.
11. Jones AW, Karlsson L. Relation between blood- and urine-amphetamine concentrations in impaired drivers in relation to urinary pH and creatinine. Human Exp Toxicol. 2005;24:615-622.
12. Kronstrand R, Jones AW. Drugs of abuse; analysis. In: Siegel JA, Saukko PJ, Knupfer GC, eds. Encyclopedia of Forensic Sciences. London: Academic Press; 2000:598-610.
13. Uges DRA. TIAFT reference blood level list of therapeutic and toxic substances (last updated 2004). Available at: www.tiaft.org/tmembers/ttvidx. html. Accessed October 6, 2006.
14. Osselton MD, Hammond MD, Moffat AC. Distribution of drugs and toxic chemicals in blood. J Forensic Sci Soc. 1980;20:187-93.
15. Jones AW, Larson H. Distribution of diazepam and nordiazepam between plasma and whole blood and the influence of hematocrit. Ther Drug Monit. 2004;26:380-385.
16. Skopp G. Preanalytic aspects in post-mortem toxicology. Forensic Sci Int. 2004;142:75-100.
17. Christophersen AS, Ceder G, Kristinsson J, et al. Drugged driving in the Nordic countries - a comparison study between five countries. Forensic Sci Int. 1999;106:173-190.
18. Jones AW, Holmgren A, Holmgren P. High concentrations of diazepam and nordiazepam in blood of impaired drivers: association with age, gender and spectrum of other drugs present. Forensic Sci Int. 2004;146:1-7.
19. Toennes SW, Kauert GF, Steinmeyer S, et al. Driving under the influence of drugs - evaluation of analytical data in oral fluid, serum and urine, and correlation with impairment symptoms. Forensic Sci Int. 2005;152:149-155.
20. Bramness JG, Skurtveit S, Morland J. Clinical impairment of benzodiazepines - relation between benzodiazepine concentrations and impairment in apprehended drivers. Drug Alcohol Depend. 2002;68:131-41.
21. Logan BK, Couper FJ. Zolpidem and driving impairment. J Forensic Sci. 2001;46:105-110.
22. Drover DR. Comparative pharmacokinetics and pharmacodynamics of short-acting hypnosedatives: zaleplon, zolpidem and zopiclone. Clin Pharmacokinet. 2004;43:227-238.
23. Rohrig TP, Moore CM. Zolpidem. Forensic aspects for the toxicologist and the pathologist. Forensic Science, Medicine and Pathology. 2005;1-2:81-90.
24. Garattini S. Active drug metabolites. An overview of their relevance in clinical pharmacokinetics. Clin Pharmacokinet. 1985;10:216-227.
25. Shah JC, Mason WD. Plasma codeine and morphine concentrations after a single oral dose of codeine phosphate. J Clin Pharmacol. 1990;30:764-766.
26. Inturrisi CE, Max MB, Foley M, et al. The pharmacokinetics of heroin in patients with chronic pain. N Engl J Med. 1984;310:1213-1217.
27. Logan BK, Case GA, Gordon AM. Carisoprodol, meprobamate and driving impairment. J Forensic Sci. 2000;45:619-623.
28. Rutherford DM, Okoko A, Tyrer PJ. Plasma concentrations of diazepam and desmethyldiazepam during chronic diazepam therapy. Br J Clin Pharmacol. 1978;6:69-73.
29. Kuitunen T, Meririnne E, Seppälä T. Correlation between blood diazepam concentrations and performance on the clinical test for drunkenness in acute and chronic diazepam users. J Traffic Med. 1994;22:105-111.
30. Greenblatt DJ, Laughren TP, Allen MD, et al. Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy. Br J Clin Pharmacol. 1981;11:35-40.
31. Mandelli M, Tognoni G, Garattini S. Clinical pharmacokinetics of diazepam. Clin Pharmacokinet. 1978;3:72-91.
32. Kronstrand R, Jones AW. Concentration ratios of codeine-to-morphine in plasma after a single oral dose (100 mg) of codeine phosphate. J Anal Toxicol. 2001;25:486-487.
33. Ceder G, Jones AW. Concentration ratios of morphine to codeine in blood of impaired drivers as evidence of heroin use and not dedication with codeine. Clin Chem. 2001;47:1980-1984.
34. Hausken AM, Skurtveit S, Christophersen AS. Characteristics of drivers testing positive for heroin or ecstasy in Norway. Traffic Inj Prev. 2004;5:107-111.
35. Christophersen AS, Ceder G, Kristinsson J, et al. Drugged driving in the Nordic countries - a comparative study between five countries. Forensic Sci Int. 1999;106:173-190.
36. O'Neal CL, Poklis A, Lichtman AH. Acetylcodeine, an impurity of illicitly manufactured heroin, elicits convulsions, antinociception, and locomotor stimulation in mice. Drug Alcohol Depend. 2001;65:37-43.
37. Jones AW. Heroin use by motorists in Sweden verified by analysis of 6-acetyl morphine in urine. J Anal Toxicol. 2001;25:353-355.
38. Bramness JG, Skurtveit S, Fauske L, et al. Association between blood carisoprodol:meprobamate concentration ratios and CYP2C19 genotype in carisoprodol-drugged drivers: decreased metabolic capacity in heterozygous CYP2C19*1/CYP2C19*2 subjects? Pharmacogenetics. 2003;13:383-388.
39. Lillsunde P, Korte T, Michelson L, et al. Drugs usage of drivers suspected of driving under the influence of alcohol and/or drugs. A study of one week's samples in 1979 and 1993 in Finland. Forensic Sci Int. 1996;77:119-129.
40. Behrensdorff I, Steentoft A. Medicinal and illegal drugs among Danish car drivers. Accid Anal Prev. 2003;35:851-860.
41. Drummer OH, Gerostamoulos J, Batziris H, et al. The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prev. 2004;36:239-248.
42. Longo MC, Hunter CE, Lokan RJ, et al. The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability: part II: the relationship between drug prevalence and drug concentration, and driver culpability. Accid Anal Prev. 2000;32:623-632.
43. Brookoff D, Cook CS, Williams C, et al. Testing reckless drivers for cocaine and marijuana. N Engl J Med. 1994;331:318-22.
44. Mura P, Chatelain C, Dumestre V, et al. Use of drugs of abuse in less than 30-year old drivers killed in a road crash in France: a spectacular increase for cannabis, cocaine and amphetamines. Forensic Sci Int. 2006;160:168-172.
45. Jones AW, Holmgren A. Abnormally high concentrations of amphetamine in blood of impaired drivers. J Forensic Sci. 2005;50:1215-1220.
46. Logan BK. Methamphetamine and driving. J Forensic Sci. 1996;41:457-465.
47. Musshoff F. Illegal or legitimate use - precursor compounds to amphetamine and methamphetamine. Drug Metab Rev. 2000;32:15-44.
48. Ingum J, Pettersen G, Sager G, et al. Relationship between unbound plasma concentrations and various psychomotor and subjective effects after intakes of diazepam and flunitrazepam. Int Clin Psychopharmacol. 1994;9:115-121.
49. Bramness JG, Skurtveit S, Morland J. Flunitrazepam: psychomotor impairment, agitation and paradoxical reactions. Forensic Sci Int. 2006;159:83-91.
50. Movig KL, Mathijssen MP, Nagel PH, et al. Psychoactive substance use and the risk of motor vehicle accidents. Accid Anal Prev. 2004;36:631-636.
51. Fraser AD. Use and abuse of the benzodiazepines. Ther Drug Monit. 1998;20:481-489.
52. Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 1997;278:27-31.
53. Ray WA, Fought RL, Decker MD. Psychoactive drugs and the risk of injurious motor vehicle crashes in elderly drivers. Am J Epidemiol. 1992;136:873-883.
54. Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet. 1998;352:1331-1336.
55. Greenblatt DJ, Harmatz JS, Friedman HH. A large sample study of diazepam pharmacokinetics. Ther Drug Monit. 1989;11:652-657.
56. Friedman H, Greenblatt DJ, Peters GR, et al. Pharmacokinetics and pharmacodynamics of oral diazepam: effect of dose, plasma concentration, and time. Clin Pharmacol Ther. 1992;52:139-150.
57. Laurijssens BE, Greenblatt DJ. Pharmacokinetic-pharmacodynamic relationships for benzodiazepines. Clin Pharmacokinet. 1996;30:52-76.
58. Wickstrom E, Amrein R, Haefelfinger P, et al. Pharmacokinetic and clinical observations on prolonged administration of flunitrazepam. Eur J Clin Pharmacol. 1980;17:189-196.
59. Greenblatt DJ, Shaader RI. Pharmacokinetics in Clinical Practice. Philadelphia: WB Saunders Co; 1985:1-125.
60. Bareggi SR, Pirola R, Truci G, et al. Effect of after-dinner administration on the pharmacokinetics of oral flunitrazepam and loprazolam. J Clin Pharmacol. 1988;28:371-375.
61. Klotz U, Avant GR, Hoyumpa A, et al. The effects of age and liver disease on the disposition and elimination of diazepam in adult man. J Clin Invest. 1975;55:347-359.
62. Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet. 2006;45:957-964.
63. Cheymol G. Effects of obesity on pharmacokinetics: implications for drug therapy. Clin Pharmacokinet. 2000;39:215-231.
64. Cotreau MM, von Moltke LL, Greenblatt DJ. The influence of age and sex on the clearance of cytochrome P450 3A substrates. Clin Pharmacokinet. 2005;44:33-60.
65. Dawling S, Crome P. Clinical pharmacokinetic considerations in the elderly - an update. Clin Pharmacokinet. 1989;17:236-363.
66. Drouet-Coassolo C, Iliadis A, Coassolo P, et al. Pharmacokinetics of flunitrazepam following single dose oral administration in liver disease patients compared with healthy volunteers. Fundam Clin Pharmacol. 1990;4:643-651.
67. Vainio A, Ollila J, Matikainen E, et al. Driving ability in cancer patients receiving long-term morphine analgesia. Lancet. 1995;346 667-670.
68. Burt M, Kloss J, Apple FS. Postmortem blood free and total morphine concentrations in medical examiner cases. J Forensic Sci. 2001;46:1138-1142.
69. Cascarbi I. Pharmacogenetics of cytochrome P4502D6 genetic background and clinical implications. Eur J Clin Invest. 2003;33(Suppl 2):17-22.
70. Meyer UA. Pharmacogenetics of adverse drug reactions. Lancet. 2000;356:1667-1671.
71. Rogers JF, Nafziger AN, Bertino JS Jr. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am J Med. 2002;113:746-750.
72. Fagerlund TH, Braaten O. No pain relief from codeine...? An introduction to pharmacogenomics. Acta Anesthesiol Scand. 2001;45:140-149.
73. Gasche Y, Daali Y, Fathi M, et al. Codeine intoxication associated with ultrarapid CYP2D6 metabolism. N Engl J Med. 2004;351:2827-2831.
74. Kirchheiner J, Schmidt H, Tzvetkov M. Pharmacokinetics of codeine and its metabolite morphine in ultra-rapid metabolizers due to CYP2D6 duplication. Pharmacogenomic J. 2006; Jul 4 [Epub ahead of print].
75. Koren G, Cains J, Chitayat D, et al. Pharmacogenetics of morphine poisoning in a breastfed neonate of a codeine-prescribed mother. Lancet. 2006;368:704.
76. Juurlink DN, Mamdani M, Kopp A, et al. Drug-drug interactions among elderly patients hospitalized for drug toxicity. JAMA. 2003;299:1652-1658.
77. Koch-Weser J, Sellers EM. Drug therapy. Binding of drugs to serum albumin (first of two parts). N Engl J Med. 1976;294:311-316.
78. Koch-Weser J, Sellers EM. Drug therapy. Binding of drugs to serum albumin (second of two parts). N Engl J Med. 1976;294:526-531.
79. Maguire KP, Burrows GD, Norman TR, et al. Blood/plasma distribution ratios of psychotropic drugs. Clin Chem. 1980;26:1624-1625.
80. Ingum J, Pettersen G, Sager G, et al. Relationship between unbound plasma concentrations and various psychomotor and subjective effects after intakes of diazepam and flunitrazepam. Int Clin Psychopharmacol. 1994;9:115-121.
81. Hinderling PH. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev. 1997;49:279-295.
82. Jochemsen R, van Boxtel CJ, Hermans J, et al. Kinetics of five benzodiazepine hypnotics in healthy subjects. Clin Pharmacol Ther. 1983;34:42-47.
83. Greenblatt DJ, Shader RI, Divoll M, et al. Benzodiazepines: a summary of pharmacokinetic properties. Br J Clin Pharmacol. 1981;11(Suppl 1):11S-16S.
84. Greenblatt DJ, Laughren TP, Divoll Allan M, et al. Plasma diazepam and desmethyldiazepam concentrations during long-term diazepam therapy. Br J Clin Pharmacol. 1981;11:35-40.
85. Olubodun JO, Ochs HR, von Moltke LL, et al. Pharmacokinetic properties of zolpidem in elderly and young adults: possible modulation by testosterone in men. Br J Clin Pharmacol. 2003;56:297-304.
86. Olubodun JO, Ochs HR, Trüten V, et al. Zolpidem pharmacokinetic properties in young females: influence of smoking and oral contraceptive use. J Clin Pharmacol. 2002;42:1142-1146.
87. Fraser AG. Pharmacokinetic interactions between alcohol and other drugs. Clin Pharmacokinet. 1997;33:79-90.
88. Juhl RP, van Thiel DH, Dittert LW, et al. Alprazolam pharmacokinetics in alcoholic liver disease. J Clin Pharmacol. 1984;24:113-119.
89. Bailey DN, Briggs JR. The binding of selected therapeutic drugs to human serum alpha-1 acid glycoprotein and to human serum albumin in vitro. Ther Drug Monit. 2004;26:40-43.
90. Flanagan RJ, Yusufi B, Barnes TRE. Comparability of whole-blood and plasma clozapine and norclozapine concentrations. Br J Clin Pharmacol. 2003;56:135-138.